Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 24;24(19):14499.
doi: 10.3390/ijms241914499.

Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis

Ernesto Fedele  1   2
Affiliations
Review

Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis

Ernesto Fedele. Int J Mol Sci. .

Abstract

Over the past 30 years, the majority of (pre)clinical efforts to find an effective therapy for Alzheimer's disease (AD) focused on clearing the β-amyloid peptide (Aβ) from the brain since, according to the amyloid cascade hypothesis, the peptide was (and it is still considered by many) the pathogenic determinant of this neurodegenerative disorder. However, as reviewed in this article, results from the numerous clinical trials that have tested anti-Aβ therapies to date indicate that this peptide plays a minor role in the pathogenesis of AD. Indeed, even Aducanumab and Lecanemab, the two antibodies recently approved by the FDA for AD therapy, as well as Donanemab showed limited efficacy on cognitive parameters in phase III clinical trials, despite their capability of markedly lowering Aβ brain load. Furthermore, preclinical evidence demonstrates that Aβ possesses several physiological functions, including memory formation, suggesting that AD may in part be due to a loss of function of this peptide. Finally, it is generally accepted that AD could be the result of many molecular dysfunctions, and therefore, if we keep chasing only Aβ, it means that we cannot see the forest for the trees.

Keywords: Alzheimer’s disease; Aβ antibodies; amyloid cascade hypothesis; clinical trials.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. The Global Dementia Observatory—World Health Organization. [(accessed on 20 September 2023)]. Available online: https://iris.who.int/bitstream/handle/10665/272669/WHO-MSD-MER-18.1-eng.....
    1. Winblad B., Amouyel P., Andrieu S., Ballard C., Brayne C., Brodaty H., Cedazo-Minguez A., Dubois B., Edvardsson D., Feldman H., et al. Defeating Alzheimer’s Disease and Other Dementias: A Priority for European Science and Society. Lancet Neurol. 2016;15:455–532. doi: 10.1016/S1474-4422(16)00062-4. - DOI - PubMed
    1. Piaceri I. Genetics of Familial and Sporadic Alzheimer s Disease. Front. Biosci. 2013;E5:E605. doi: 10.2741/E605. - DOI - PubMed
    1. Andrade-Guerrero J., Santiago-Balmaseda A., Jeronimo-Aguilar P., Vargas-Rodríguez I., Cadena-Suárez A.R., Sánchez-Garibay C., Pozo-Molina G., Méndez-Catalá C.F., Cardenas-Aguayo M.-D.-C., Diaz-Cintra S., et al. Alzheimer’s Disease: An Updated Overview of Its Genetics. Int. J. Mol. Sci. 2023;24:3754. doi: 10.3390/ijms24043754. - DOI - PMC - PubMed
    1. Armstrong R.A. Risk Factors for Alzheimer’s Disease. Folia Neuropathol. 2019;57:87–105. doi: 10.5114/fn.2019.85929. - DOI - PubMed

MeSH terms

Grants and funding

The University of Genoa supported this study (FRA UniGe 2023 to EF).